UCD19 CAR T Cells
/ University of Colorado
- LARVOL DELTA
Home
Next
Prev
1 to 20
Of
20
Go to page
1
November 04, 2025
UCD19 CAR-T cell therapy for adults with B-cell acute lymphoblastic leukemia in first complete remission with MRD positivity: Preliminary Results of A phase I/ib clincal trial
(ASH 2025)
- "All three patients with NGS-MRD recurrence became NGS-MRD negative after one cycle of blinatumomab and were subsequently consolidated with allogeneic stemcell transplant. Low disease burden relapses (detected by NGS-MRD)occurred in some patients who had loss of BCA within 6 months of infusion. Enrollment in the phase 1bdose expansion at DL2 is ongoing."
CAR T-Cell Therapy • Clinical • IO biomarker • Minimal residual disease • P1 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • CRLF2 • EBF1 • KMT2A • PDGFRB • TP53
December 07, 2024
Use of CD19 CAR-T Cells in Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Minimal Residual Disease (MRD) Positivity at First Complete Remission: Preliminary Outcomes from a Phase I Clinical Trial
(ASH 2024)
- "Incorporation of blinatumomab and/or inotuzumab in CR1 may mitigate the negative prognostic significance of MRD, however it is unclear if intensity of standard post-remission therapy can be safely reduced without compromising outcomes...We designed a phase I clinical trial to determine safety and tolerability of UCD19 CAR-T cell therapy for adults with B-ALL in MRD+ CR1 who are at high risk for relapse.Methods : Eligible patients include adults (≥18yo) with B-ALL in CR1 after induction therapy, with MRD positivity by either flow cytometry or NGS (Clonoseq)...Longer follow-up is needed to determine if remissions remain durable, and to determine the relationship between functional persistence (as measured by B-cell aplasia) and remission durability. Enrollment is ongoing at DL2."
CAR T-Cell Therapy • Clinical • Minimal residual disease • P1 data • Residual disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • Septic Shock • Thrombocytopenia • CXCL8 • IFNG • IL6 • TNFA
May 15, 2025
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
(clinicaltrials.gov)
- P1 | N=10 | Completed | Sponsor: University of Colorado, Denver | Active, not recruiting ➔ Completed
Trial completion • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19
April 15, 2025
UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
(clinicaltrials.gov)
- P1 | N=29 | Recruiting | Sponsor: University of Colorado, Denver | N=14 ➔ 29 | Trial completion date: Jul 2027 ➔ Jun 2030 | Trial primary completion date: Jul 2025 ➔ Jun 2027
Enrollment change • Minimal residual disease • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR
February 16, 2025
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
(clinicaltrials.gov)
- P1 | N=11 | Active, not recruiting | Sponsor: University of Colorado, Denver | Trial completion date: Dec 2024 ➔ Dec 2025
Trial completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19
May 03, 2024
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
(clinicaltrials.gov)
- P1 | N=11 | Active, not recruiting | Sponsor: University of Colorado, Denver | Trial completion date: Dec 2023 ➔ Dec 2024
Trial completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19
January 01, 2024
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
(clinicaltrials.gov)
- P1/2 | N=50 | Recruiting | Sponsor: University of Colorado, Denver
CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD19
October 01, 2023
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
(clinicaltrials.gov)
- P1 | N=11 | Active, not recruiting | Sponsor: University of Colorado, Denver | Trial primary completion date: Dec 2023 ➔ Mar 2023
Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19
July 07, 2023
UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
(clinicaltrials.gov)
- P1 | N=14 | Recruiting | Sponsor: University of Colorado, Denver | Not yet recruiting ➔ Recruiting | Trial completion date: Apr 2026 ➔ Jul 2027 | Initiation date: Dec 2023 ➔ Jul 2023 | Trial primary completion date: Apr 2025 ➔ Jul 2025
CAR T-Cell Therapy • Enrollment open • Minimal residual disease • Trial completion date • Trial initiation date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR
July 07, 2023
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
(clinicaltrials.gov)
- P1 | N=11 | Active, not recruiting | Sponsor: University of Colorado, Denver | Trial primary completion date: Dec 2022 ➔ Dec 2023
Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19
January 31, 2023
UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
(clinicaltrials.gov)
- P1 | N=14 | Not yet recruiting | Sponsor: University of Colorado, Denver | Initiation date: Dec 2022 ➔ Dec 2023
CAR T-Cell Therapy • Minimal residual disease • Trial initiation date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR • CD19
September 10, 2022
UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
(clinicaltrials.gov)
- P1 | N=14 | Not yet recruiting | Sponsor: University of Colorado, Denver
CAR T-Cell Therapy • Minimal residual disease • New P1 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR • CD19
September 02, 2022
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
(clinicaltrials.gov)
- P1 | N=11 | Active, not recruiting | Sponsor: University of Colorado, Denver | Recruiting ➔ Active, not recruiting | N=20 ➔ 11
Enrollment change • Enrollment closed • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19
August 12, 2022
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: University of Colorado, Denver | Trial completion date: Dec 2022 ➔ Dec 2023
Trial completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19
August 19, 2021
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
(clinicaltrials.gov)
- P1/2; N=50; Recruiting; Sponsor: University of Colorado, Denver; Trial completion date: Jul 2021 ➔ Jul 2026; Trial primary completion date: Jun 2021 ➔ Jun 2026
CAR T-Cell Therapy • Clinical • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD19
June 23, 2021
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
(clinicaltrials.gov)
- P1; N=20; Recruiting; Sponsor: University of Colorado, Denver; Trial completion date: Mar 2024 ➔ Dec 2022; Trial primary completion date: Mar 2024 ➔ Dec 2022
Clinical • Trial completion date • Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19
March 23, 2021
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
(clinicaltrials.gov)
- P1/2; N=50; Recruiting; Sponsor: University of Colorado, Denver; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD19
June 19, 2020
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
(clinicaltrials.gov)
- P1; N=20; Recruiting; Sponsor: University of Colorado, Denver; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
April 28, 2020
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
(clinicaltrials.gov)
- P1; N=20; Not yet recruiting; Sponsor: University of Colorado, Denver; Initiation date: Mar 2020 ➔ Sep 2020
Clinical • Trial initiation date • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
January 27, 2020
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
(clinicaltrials.gov)
- P1; N=20; Not yet recruiting; Sponsor: University of Colorado, Denver
Clinical • New P1 trial
1 to 20
Of
20
Go to page
1